» Articles » PMID: 38482020

Immunogenicity of Chimeric Hemagglutinins Delivered by an Orf Virus Vector Platform Against Swine Influenza Virus

Overview
Journal Front Immunol
Date 2024 Mar 14
PMID 38482020
Authors
Affiliations
Soon will be listed here.
Abstract

Orf virus (ORFV) is a large DNA virus that can harbor and efficiently deliver viral antigens in swine. Here we used ORFV as a vector platform to deliver chimeric hemagglutinins (HA) of Influenza A virus of swine (IAV-S). Vaccine development against IAV-S faces limitations posed by strain-specific immunity and the antigenic diversity of the IAV-S strains circulating in the field. A promising alternative aiming at re-directing immune responses on conserved epitopes of the stalk segment of the hemagglutinin (HA2) has recently emerged. Sequential immunization with chimeric HAs comprising the same stalk but distinct exotic head domains can potentially induce cross-reactive immune responses against conserved epitopes of the HA2 while breaking the immunodominance of the head domain (HA1). Here, we generated two recombinant ORFVs expressing chimeric HAs encoding the stalk region of a contemporary H1N1 IAV-S strain and exotic heads derived from either H6 or H8 subtypes, ORFVcH6/1 and ORFVcH8/1, respectively. The resulting recombinant viruses were able to express the heterologous protein . Further, the immunogenicity and cross-protection of these vaccine candidates were assessed in swine after sequential intramuscular immunization with OV-cH6/1 and OV-cH8/1, and subsequent challenge with divergent IAV-S strains. Humoral responses showed that vaccinated piglets presented increasing IgG responses in sera. Additionally, cross-reactive IgG and IgA antibody responses elicited by immunization were detected in sera and bronchoalveolar lavage (BAL), respectively, by ELISA against different viral clades and a diverse range of contemporary H1N1 IAV-S strains, indicating induction of humoral and mucosal immunity in vaccinated animals. Importantly, viral shedding was reduced in nasal swabs from vaccinated piglets after intranasal challenge with either Oh07 (gamma clade) or Ca09 (npdm clade) IAV-S strains. These results demonstrated the efficiency of ORFV-based vectors in delivering chimeric IAV-S HA-based vaccine candidates and underline the potential use of chimeric-HAs for prevention and control of influenza in swine.

Citing Articles

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster.

Esen M, Fischer-Herr J, Gabor J, Gaile J, Fleischmann W, Smeenk G Vaccines (Basel). 2024; 12(11).

PMID: 39591190 PMC: 11599021. DOI: 10.3390/vaccines12111288.


Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2.

Metz C, Haug V, Muller M, Amann R Vaccines (Basel). 2024; 12(5).

PMID: 38793743 PMC: 11126055. DOI: 10.3390/vaccines12050492.


Identification of an Immunodominant B-Cell Epitope in African Swine Fever Virus p30 Protein and Evidence of p30 Antibody-Mediated Antibody Dependent Cellular Cytotoxicity.

Noll J, Rani R, Butt S, Fernandes M, do Nascimento G, Martins M Viruses. 2024; 16(5).

PMID: 38793639 PMC: 11125664. DOI: 10.3390/v16050758.

References
1.
Jegaskanda S, Reading P, Kent S . Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J Immunol. 2014; 193(2):469-75. DOI: 10.4049/jimmunol.1400432. View

2.
Garten R, Davis C, Russell C, Shu B, Lindstrom S, Balish A . Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009; 325(5937):197-201. PMC: 3250984. DOI: 10.1126/science.1176225. View

3.
Hemann E, Kang S, Legge K . Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol. 2013; 191(5):2486-94. PMC: 3777857. DOI: 10.4049/jimmunol.1300954. View

4.
Rohde J, Schirrmeier H, Granzow H, Rziha H . A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV). Vaccine. 2011; 29(49):9256-64. DOI: 10.1016/j.vaccine.2011.09.121. View

5.
Diel D, Luo S, Delhon G, Peng Y, Flores E, Rock D . A nuclear inhibitor of NF-kappaB encoded by a poxvirus. J Virol. 2010; 85(1):264-75. PMC: 3014193. DOI: 10.1128/JVI.01149-10. View